Toggle light / dark theme

Oxford BioTherapeutics (OBT) has entered a multi-year partnership with Roche to discover antibody-based therapeutics for cancer treatment.

The partnership will leverage OBT’s OGAP-Verify discovery platform, which claims to offer greater sensitivity and enables target selection with enhanced drug development attributes.


OBT has entered a multi-year partnership with Roche to discover antibody-based therapeutics for cancer treatment.

Leave a Comment

If you are already a member, you can use this form to update your payment info.

Lifeboat Foundation respects your privacy! Your email address will not be published.